Publications


5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.
Proc Natl Acad Sci U S A 2018 Feb 5. Epub 2018 Feb 5.
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892;



Report of the results of the International Clinical Cytometry Society and American Society for Clinical Pathology workload survey of clinical flow cytometry laboratories.
Cytometry B Clin Cytom 2017 Nov 3;92(6):525-533. Epub 2016 Aug 3.
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.












Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
J Clin Oncol 2015 Feb 25;33(6):540-9. Epub 2014 Aug 25.
James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Robert P.T. Somerville, Robert O. Carpenter, Maryalice Stetler-Stevenson, James C. Yang, Q. Phan, Marybeth S. Hughes, Richard M. Sherry, Mark Raffeld, Steven Feldman, Lily Lu, Yong F. Li, Lien T. Ngo, Debbie-Ann N. Nathan, Kathleen E. Morton, Mary Ann Toomey, and Steven A. Rosenberg, National Cancer Institute; Clara C. Chen, Clinical Center, National Institutes of Health (NIH); Sarah M. Kranick and Avindra Nath, National Institutes of Neurologic Disorders and Stroke, NIH, Bethesda, MD; Andre Goy and Tatyana Feldman, Hackensack University Medical Center, Hackensack, NJ; David E. Spaner, Sunybrook Odette Cancer Center, Toronto, Ontario, Canada; and Michael L. Wang, MD Anderson Cancer Center, Houston, TX.



Paradoxical central nervous system immune reconstitution syndrome in acquired immunodeficiency syndrome-related primary central nervous system lymphoma.
Haematologica 2015 Jan 10;100(1):e21-4. Epub 2014 Oct 10.
HIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute; National Institutes of Health



A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
Haematologica 2014 Jun 21;99(6):e81-3. Epub 2014 Mar 21.
Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA


Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia.
Am J Clin Pathol 2013 Dec;140(6):813-8
Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Bethesda, MD, 20892;

Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.
Clin Cancer Res 2013 Dec 25;19(24):6873-81. Epub 2013 Nov 25.
Authors' Affiliations: Laboratories of Molecular Biology, Pathology, and Metabolism Branch, National Cancer Institute; and Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, Maryland.


Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia.
Exp Hematol 2013 Sep 18;41(9):772-8. Epub 2013 May 18.
Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.
Leuk Res 2013 Apr 22;37(4):401-409. Epub 2013 Jan 22.
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address:

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Blood 2013 Feb 14;121(7):1165-74. Epub 2012 Dec 14.
Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.

Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.
Am J Hematol 2012 Sep 4;87(9):916-22. Epub 2012 Apr 4.
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.



Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia.
Leuk Lymphoma 2011 Dec 12;52(12):2284-92. Epub 2011 Jul 12.
Laboratory of Stem Cell Biology, Cellular and Tissue Therapy Branch, Division of Cell and Gene Therapies,Office of Cellular, Tissues and Gene Therapies, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.






Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Clin Cancer Res 2010 Mar 9;16(6):1894-903. Epub 2010 Mar 9.
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-1104, USA.


Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
J Clin Oncol 2009 Nov 13;27(32):5410-7. Epub 2009 Oct 13.
Departmentof Health and Human Services, Center for Cancer Researchand Cancer Therapy EvaluationProgram, National Cancer Institute,National Institutes of Health, Bethesda, USA.

Persistent non-neoplastic gammadelta-T cells in cerebrospinal fluid of a patient with hepatosplenic (gammadelta) T cell lymphoma: a case report with 6 years of flow cytometry follow-up.
Int J Clin Exp Pathol 2009 Oct 15;3(1):110-6. Epub 2009 Oct 15.
Laboratory of Pathology, Hematopathology Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Br J Haematol 2009 Apr 19;145(2):173-9. Epub 2009 Feb 19.
Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.
Clin Cancer Res 2009 Apr 17;15(7):2514-22. Epub 2009 Mar 17.
Metabolism Branch, Center for Cancer Research, Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland and MedImmune, Inc, Gaithersburg, Maryland, USA.

TIMP1 induces CD44 expression and the activation and nuclear translocation of SHP1 during the late centrocyte/post-germinal center B cell differentiation.
Cancer Lett 2008 Sep 23;269(1):37-45. Epub 2008 May 23.
Department of Pathology, Korea University Ansan Hospital, 516 Gojan-1 Dong, Danwon-Gu, Gyeonggi-Do, Ansan 425-707, Republic of Korea.

Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation.
Br J Haematol 2007 Dec;139(5):824-31
Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.


Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy.
Cancer Immunol Immunother 2006 Sep 26;55(9):1100-10. Epub 2005 Nov 26.
Laboratories of Molecular Biology and Pathology, and Biostatistics and Data Management Section, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.
Nat Med 2005 Sep 21;11(9):986-91. Epub 2005 Aug 21.
Experimental and Transplantation Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, USA.



OF